Your browser doesn't support javascript.
loading
Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.
Novak, Jennifer; Salgia, Ravi; West, Howard; Villalona-Calero, Miguel A; Sampath, Sagus; Williams, Terence; Villaflor, Victoria; Massarelli, Erminia; Pathak, Ranjan; Koczywas, Marianna; Chau, Brittney; Amini, Arya.
Afiliación
  • Novak J; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Salgia R; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • West H; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Villalona-Calero MA; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Sampath S; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Williams T; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Villaflor V; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Massarelli E; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Pathak R; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Koczywas M; Department of Medical Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Chau B; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
  • Amini A; Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA 91010, USA.
Cancers (Basel) ; 14(16)2022 Aug 18.
Article en En | MEDLINE | ID: mdl-36010982
Tyrosine kinase inhibitor (TKI) therapy is the recommended first-line treatment for metastatic non-small-cell lung cancer (NSCLC) positive for epidermal growth factor receptor (EGFR) gene mutation. However, most individuals treated with TKI therapy for EGFR-mutant NSCLC will develop tumor resistance to TKI therapy. Therapeutic strategies to overcome TKI resistance are the topic of several ongoing clinical trials. One potential strategy, which has been explored in numerous trials, is the treatment of progressive sites of disease with stereotactic body radiation treatment (SBRT) or stereotactic radiosurgery (SRS). We sought to review the literature pertaining to the use of local ablative radiation therapy in the setting of acquired resistance to TKI therapy and to discuss stereotactic radiation therapy as a strategy to overcome TKI resistance.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza